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ABSTRACT 
Aim and Objectives: The present study was aimed to evaluate anti parkinsonium effect of Betaine for its Applications in trigger factors in 
pathogenesis of Parkinson’s disease and to understand development of new treatments approaches for PD. Betaine is naturally obtained 
product. It has antioxidant, neuroprotective activity. Hence, we inspected whether betaine can act as a protective agent in 6-OHDA induced 
oxidative stress on cerebellum of Sprague-Dawleyrats.  
Material and Methods Thirty-six adult Sprague-Dawley rats were dived into six groups. Rats were received unilateral 6- 
hydroxydopamine lesions for induction except normal and rats were treated with respective treatment. At the day of 21 rats were 
sacrificed. Prepared brain homogenate was used for further Biochemical estimation.  
Result: Betaine showed marked rise in SOD and Catalase activity as well as GSH content subsequently decreasing in the lipid peroxidation 
process. Our result suggests Betaine to be potent antioxidant at dose 12.5 and 25 mg/kg as compared to standard (L-dopa+Benserazide) 
and pro-inflammatory cytokines viz: TNF-α, IL-1β and IL-6 were significantly reversed by Betaine as compared to that of standard group 
(L-dopa+ Benserazide). 
Discussion and Conclusion: Betaine showed dose dependent effect by reducing LPO level as increasing SOD, GSH and Catalase activity and 
marked reduced proinflammatory cytokine, hence we conclude that betaine has good anti parkinsonism activity.  
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INTRODUCTION 
Parkinsonism (PD) is slowly progressive 
neurodegenerative disease caused due to die of brain cell 
that control body movements. It is described by James 
Parkinson in 1817. It is mainly characterised clinically by 
bradykinesia, tremor, rigidity and postural instability1. 
Prevalence of PD increase with age near about 1% people 
with above 60 age affected by parkinsonism2. In 
pathophysiology of PD increase in cytokine level as 
increases the oxidative stress as well as change in 
behavioural changes occurs3.  6-Hydroxydopamine (6-
OHDA)-induced neurodegeneration is a well known 
experimental model for PD. It is selectively taken up by the 
dopamine transporters of dopaminergic neurons, and it 
induces retrograde neurodegeneration. Thus, 6-OHDA 
injections into the striatum or medial forebrain bundle 
induce nigral degeneration that then results in 
characteristic behavior abnormalities with change 
biochemical parameters in experimental animals4,5. 
Betaine is found in plants, animals and microorganisms 
and is a significant component of many foods, including 
wheat, shellfish, spinach, and sugar beets6.  It is a zwitter 
ionic quaternary ammonium compound that is also known 
as trimethylglycine, glycine betaine, lycine, and 
oxyneurine. It has physiologic function either as an organic 
osmolyte to protect cells under stress. The principle role of 
Betaine is to protect cells against osmotic inactivation in 
plants and microorganisms. Betaine synthesis is triggered 
due to exposure to drought, high salinity, or temperature 
stress, which results in its accumulation in the cells. It 
increases the water retention of cells, replaces inorganic 
salts, and protects intracellular enzymes against 
temperature-induced or osmotically induced inactivation 
as it is a compatible osmolyte7. It has been reported as 
Betaine is for the number of several conditions of disease 
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involving brain, heart and kidney. It also has potential as a 
neuroprotective agent for prevention of LD induced 
oxidative damage in brain tissue of rats. It has been 
demonstrated that Betaine may have a potential as a 
neuroprotective agent for prevention of LD induced 
oxidative damage in cerebellum and Benserazide mediated 
hyperhomocysteinemia in rats8. It prevents ethanol-
induced oxidative stress and reduces total homocysteine 
in the rat cerebellum7. In suggesting Betaine may have a 
therapeutic neuroprotective effect of PD. It is also has been 
used in the treatment of elevated homocysteine10. 
MATERIAL AND METHODS 
Animals and groups 
Sprague-Dawley male rats with 200-250 gm were used for 
this study. Animal were procured from National Institue of 
Bioscience (CPCSEA reg. no. 1139/a/07/CPCSEA) and 
housed at the Institute Animal House at standard 
laboratory conditions with a temperature of 25±1°C, 
relative humidity of 50–65% and 12:12 h dark and light 
cycle. Animals had free access to food (Standard chaw 
pellets, Nutrivet life sciences, Pune) and water with ad 
libitum. The experimental protocol (Protocol approval no. 
SIOP/IAEC/2017/02/03) was approved by the 
Institutional Animal Ethics Committee (IAEC) constituted 
in accordance with the rules and guidelines of the 
Committee for the Purpose of Control and Supervision on 
Experimental Animals, India (CPCSEA).  
Chemicals and Drugs 
Betaine, Apomorphine hydrochloride hemihydrates, 
Desipramine HCL, 6-Hydroxydopamine Hydrochloride, 
Benserazide Sigma Aldrich), Ketamine (Themis Medicare), 
Xyalazine (Indian Immunological LTD. Telangana.), L-
Dopa, Dopamine (Aqua Fine Injecta PVT. LTD. Pune), 
Haloperidol (RPG Lifescience). 
Experimental Protocol  
Two weeks after surgery, rats were randomly divided into 
six groups based on the number of contralateral rotations 
Group 1: Normal- received vehicle for 21 days 
Group 2:  Control- Rats received unilateral 6- 
hydroxydopamine 
Group 3: Standard - received 6- hydroxydopamine + L-
Dopa 10mg/kg along with Benserazide 2.5 mg/kg orally 
Group 4 to 6: Test-I, II and III- received 6- 
hydroxydopamine + 12.5mg/kg, 25 mg/kg, 50 mg/kg 
betaine orally for 21 days. 
6-Hydroxydopamine (6-OHDA) lesioning 
Rats received unilateral 6- hydroxydopamine lesions 
medial forebrain bundle to destroy DA neurons. 
Desipramine HCL (25mg/kg, i.p.) was given prior to the 6- 
OHDA injection to protect norepinephrine (NE) neurons. 
Rats were anesthetized with Ketamine (80 mg/kg, i.p.) and 
then placed in a stereotaxic apparatus (Inco Ambala, 
India). The coordinates for 6-OHDA injections were AP: -
2.5mm, ML: + 2.0 mm, DV: -9 mm relative to bregma with 
the incisor bar positioned 3.3 mm below the interaural 
line. Using a 10µl Hamilton syringe attached to a 26 gauge 
needle, 6-OHDA (12 µg) dissolved in 0.9% NaCl + 0.1% 
ascorbic acid was infused through a small blur hole in the 
skull at a rate of 2 µl/min for a total volume of 4 µl. The 
needle was withdrawn 1 m later. Two weeks after the 
surgery rats were challenged with apomorphine 
hydrochloride (0.2 mg/kg, s.c.) and contralateral rotation 
was monitored. Animals showing fewer than 20 rotations 
per 5 min were excluded from further studies10-12. 
Behavioural Parameter 
Grid test 
Gridiron of 30 cm wide and 35 cm high with a space of 1.2 
cm between each wire was used. Each rat was hung by all 
four paws on the vertical grid and stopwatch was started 
as the rat was held on the grid. A stopwatch was stopped 
and time taken by the rats was noted as descent latency. 
The maximum cut of time was 180 seconds 13. 
Catalepsy Bar test 
A rat was placed with both forepaws on a bar, which was 
10 cm above the surface in half rearing position (Catalepsy 
Bar Test, VJ Instruments India). The maximum cut of time 
for 180 seconds14. 
Locomotor Activity 
Spontaneous locomotor activity was assessed in the 
Actophotoactometer. Rats were placed in Digital 
Photoactometer the center allowed to freely explore it for 
5 min.  Evaluate the total no. of counts as an indicator of 
spontaneous locomotor activity15. 
Evaluation of the oxidative stress 
Estimation of Reduced Glutathione 
GSH was estimated by the method with add 0.1 ml 
supernatant into 0.9 ml of 0.001 mol/l 5, 5’-dithiobis-2-
nitrobenzoic acid (in 0.1 mol/l phosphate buffer, pH 8.0). 
The yellow color that developed was read immediately at 
412 nm (endpoint) using PowerWaveTM XS Microplate 
Spectrophotometer. GSH (Sigma Chemicals, USA) was used 
as the standard. The amount was expressed as mg of GSH 
/g of wet tissue16. 
Estimation of lipid peroxidation  
Lipid peroxidation in the brain was determined by 
measuring MDA content using the method reported by0.5 
ml homogenate added into the mixture of 3ml of 1% w/v 
Phosphoric acid and 1ml of 0.6% w/v Thiobarbituric acid. 
Heat for 45 min (boiling water bath 85oC), cool 
immediately in ice bath. Add 4ml n-butanol and vortex and 
centrifuge at 5000 rpm for 10 min. Take the absorbance of 
organic layer at 535 nm (endpoint method) using 
PowerWaveTM XS microplate spectrophotometer. 1, 1, 3, 3-
tetraethoxypropane (Sigma Chemicals, USA) was used as 
the standard MDA and levels were expressed as µg/g 
tissue17. 
Estimation of catalase  
Catalase activity was estimated with the supernatant (0.5 
mL) was added to a quartz cuvette containing 2.mL 10 mM 
H2O2 prepared in potassium phosphate buffer (50 mM, pH 
7.0). The change in absorbance was monitored at 240 nm 
from 00 sec. to 210 sec. using a Shimadzu 
spectrophotometer (UV-1201, Japan). Catalase levels were 
expressed as U/mg protein16. 
Estimation of superoxide dismutase  
SOD activity was determined with slight modifications. To 
150 µl of tissue supernatant, 2.85 ml of 0.1 M phosphate 
buffer (pH 8.4) and 50 µl of 7.5mM pyrogallol were added 
and absorbance was measured at 420 nm for 3 min at 30 s 
intervals. Enzyme levels were expressed as U/mg 
protein17. 
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Evaluation of Pro-inflammatory cytokines. 
Proinflammatory cytokine were determined in brain tissue 
homogenate. Cytokines like  Tumor Necrosis Factor- alpha 
(TNF-α), Interleukin-1-beta (IL-1β), Interleukin-6 (IL-6) 
was estimated by sandwich ELISA by using commercially 
available ELISA kits18. 
Statistical analysis 
Data was analysed by One way ANOVA followed by 
Bonferroni multiple comparison test. Data were expressed 
as mean ± SEM 
RESULTS 
Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on 
Locomotors Activity. 
Decreased locomotion count was observed in control 
group (ap<0.001) as compared to the normal. Whereas 
significant increase in locomotion count was observed 
from day 7 onwards in Test-II groups as compared to 
control group (dp<0.001) as shown in table 1. 
 
Table 1:  Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on Locomotor Activity 
Groups Day 0 Day 7 Day 14 Day 21 
Normal 764 2.057 749.51.84 709.521.07 780.331.98 
Control 710.52.09a     405.83 0.68a 385.80.76a 206.830.73a 
Standard  759.51.92c 5660.87d   649.333.97d  777.672.026d 
Test-I    750.831.82b       379.670.85ns   362.50.78ns    180.1670.37ns 
Test-II  754.51.83b     555.160.72d   630.674.06d 758.332.30d 
Test-III     740.5 1.80ns    369.30.98ns     349.830.67ns   169.6670.46ns 
 
Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on the 
cataleptic score. 
The graph shows significant increase in cataleptic score in 
6-OHDA treated animals in control (ap<0.001) group as 
compare to normal group. Whereas significant decrease in 
cataleptic score was observed in test test-I, test-II and test-
III group on day 0 and 7 (dp<0.001), as compare to control 
group as shown in table 2. 
 
Table 2: Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on the cataleptic score 
Groups Day 0 Day 7 Day 14 Day 21 
Normal 2.830.19 3.830.34 3.330.29 2.830.28 
Control    26.170.48a    27.330.51a  28.50.65 a            300.83a 
Standard   12.830.56d    19.330.40d   22.830.54c       26.670.46ns 
Test-I    13.830.51d    17.170.45d 22.50.30c      25.170.71b 
Test-II    17.170.51d  21.50.44c    24.170.58ns 270.65ns 
Test-III    17.830.46d 190.27d     25.170.59ns   29.50.78ns 
 
Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on 
decent latency. 
The graph shows effect of Betaine on descent latency i.e. 
the time taken by the rats to remove the grip from the iron 
grid. The 6-OHDA treatment significantly (ap<0.001) 
reduced descent latency on day 0, 7, 14 and 21 as compare 
to normal. Whereas significantly (dp<0.001) increase in 
decent latency was observed in test-I, test-II and test-III on 
day 0 onwards up to day 21 except test-III on day 14. As 
shown in table 3. 
 
Table 3: Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on decent latency 
Groups Day 0 Day 7 Day 14 Day 21 
Normal 23.170.20          37.330.90   33.50.83 32.330.75 
Control 5.830.19a         4.330.20a        3.830.12a 30.23a 
Standard  21.670.39d          27.830.59d        31.330.39d  28.670.49d 
Test-I 25.83067d         26.170.39d       31.670.91d  32.330.84d 
Test-II          160.3d         27.671.02d         28.830.51d  30.171.04d 
Test-III  23.330.52d      240.0.23d           24.670.36d 25.50.31d 
 
Effect of betaine on activities of Effect of Betaine (12.5, 
25 and 50 mg/kg., p.o.) on antioxidant. 
The control group shows significantly decrease in catalase 
activity as compare to normal (ap<0.01). Betaine test-I, 
test-II and test-III counteracted the deleterious effect of 6-
OHDA by increasing level of this antioxidant. SOD activity 
is increased by test-II, which is less significant (cp<0.01). 
MDA content is significantly increased in control as 
compare to normal (ap<0.001). MDA content significantly 
decreased by Betaine test-I, test-II and test-III (dp<0.001). 
GSH content is found to be decreased in control as 
compare to normal (ap<0.01) Betaine test-II increased GSH 
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Table 4: Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on antioxidant 
Groups 
Conc. of Catalase  
(U/mg of protein) 
Conc. of SOD  
    (U/mg of protein) 
MDA  
      (µg/mg 
protein) 
GSH  
   µg/mg of 
protein 
Normal 22.031.39 22.791.077     0.080.0022 4.700.11 
Control 3.1510.16a 8.3880.26a    0.860.016a    2.960.033a 
Standard 11.090.27d 16.380.77ns       0.140.0076d 4.570.10c 
Test-I 20.83 0.47d 14.360.12ns      0.190.001d   2.52 0.14ns 
Test-II 21.61 0.54d 22.080.54c         0.100.0011d 4.380.11c 
Test-III 20.820.32d 14.600.17ns           0.190.00151d   2.500.15ns 
 
Effect of Betaine (12.5, 25 and 50 mg/kg., p.o.) on pro-
inflammatory cytokines. 
The effect of Betaine on pro-inflammatory cytokines in 
control groups showed a significantly (ap<0.001) increased 
in TNF-, IL-1β and IL-6 level as compared to normal 
groups. Twenty one days of Betaine treatment in test-I, 
test-II and test-III is decreased significantly (dp<0.001) in 
TNF-, IL-1β and IL-6 level as compared to control groups 
as shown in table 5. 
 
Table 5:  Effect of betaine on pro-inflammatory cytokines 
Sr. No. Groups IL-6 IL-1 TNF- 
1 Normal 50.610.23 50.560.21 77.400.74 
2 Control 162.681.48a     143.620.64a 145.350.76a 
3 Standard 51.540.07d 51.370.09d 86.610.87d 
4 Test-I 59.210.63d   71.280.31d 97.242.11d 
5 Test-II 143.780.71d  58.500.63d 121.020.43d 
6 Test-III 142.800.54d  70.960.30d 119.690.57d 
 
DISCUSSION 
In present study we have evaluated aanti-parkinsonium 
effect of betaine in experimental rats. Parkinsonism is 
neurodegenerative disease associated with loss of 
dopaminergic neurons in substantia nigra pars 
compacta19. PD is characterized by tremor, akinesia and 
muscle rigidity. it has been proved that in PD there is 
increase in the content of TNF- α, IL-1β, IL-6 and many 
more in striatal dopaminergic region of Parkinson’s brain. 
Numerous studies support that administration of 6-OHDA 
induces neuronal toxicity. It is a hydoxylate analogue of 
dopamine which uses the same transport system as 
dopamine and nor- epinephrine to produce specific 
degeneration of catecholaminergic neurons. On ICV 
administration, 6-OHDA causes degeneration of 
dopaminergic neurons with dramatic loss of DA in 
striatum. The toxic mechanism of this compound is 
dependent on its oxidation with concomitant production of 
ROS, para and semiquinolone products201,21. Brain being 
deficient in oxidative defence mechanism is at greater risk 
of cellular damage caused by free radicals. 6-OHDA 
undergo metabolism and forms ROS. The para and 
semiquinolone products formed during oxidation of 6-
OHDA are capable of inducing cellular damage through 
reaction with nucleophile such as protein and DNA, they 
do not appear to be primarily responsible for toxic effects. 
ROS formed during its metabolism has shown to exhibit 
potential role in neurotoxicity22. This acute model has 
been used in the efficacy testing of many pharmacological, 
anti-Parkinsonism drugs. In order to understand the 
mechanism of action, we evaluated the effects of Betaine in 
6-OHDA induced PD as evident by the grip strength, 
locomotion and catalepsy score (akinesia with muscle 
rigidity) parameters. 6-OHDA treatment showed 
deterioration of above mentioned behavioural parameters 
in rats. Betaine restored these behavioural changes 
significantly. Administration of Betaine showed significant 
improvement in grip strength, catalepsy and restored 
locomotor activity in rats; these effects were comparable 
to that of standard group (L-dopa + Benserazide). Brain 
homogenates of 6-OHDA treated rats were subjected to 
biochemical estimationin terms of levels/ activity. Analysis 
of post-mortem brains from PD rats confirms the high 
level of oxidative stress in the SNPc marked by increase 
iron concentrations, decreased levels of GSH and increased 
lipid peroxidation. Betaine has showed marked rise in SOD 
and Catalase activity as well as GSH content subsequently 
decreasing in the lipid peroxidation process. Our result 
suggests Betaine to be potent antioxidant at dose 12.5 and 
25 mg/kg as compared to standard (L-dopa+Benserazide). 
Elevated inflammatory cytokines in the brain, cerebral 
spinal fluid (CSF) and plasma of PD patients supports the 
existence of functional interconnections between the 
immune and nervous systems23. Recent reports indicate 
that a pro-inflammatory event in the periphery can induce 
chronic, self-propelling neuroinflammation in the brain, 
and that systemic cytokines are critical for CNS effects in 
response to peripheral immune activation show that the 
entry of pro-inflammatory factors, such as TNF- α, to the 
brain will cause the activation of microglia to produce 
more inflammatory factors24. The factors may cause 
neuronal death, suggesting a clinical implication for the 
link between peripheral inflammation and 
neuroinflammation25. The stimulation of immune-
competent cells and hyper production of cytokines are 
considered to play a role in the development and 
progression of multiple neurodegenerative diseases. 
Peripheral inflammation may amplify the neuro-
inflammation contributing to disease pathogenesis26. The 
augmented expression of pro-inflammatory cytokines viz: 
TNF-α, IL-1β and IL-6 were significantly reversed by 
Betaine as compared to that of standard group (L-dopa+ 
Benserazide). As per literature review, Betaine is a safer 
drug possessing wide therapeutic window. It can also act 
as antioxidant agent versus oxidative stress mediated by 
antiparkinsonian drugs viz L- dopa and L-dopa+ 
Benserazide. Betaine also demonstrated a methyl donor 
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effect to reduce hyperhomocysteinemia. It appears that 
antioxidant and methyl donor properties of Betaine are 
promising particularly in management of plasma total 
homocysteine (tHcy) and oxidative stress in dopaminergic 
neurons of the brain. Betaine can be better adjuvant in 
pharmacotherapy of PD and/or to manage extrapyramidal 
side effects of anti-parkinsonian drugs like L-dopa. 
CONCLUSION 
The present study provides proof of concept for potential 
use of Betaine as an adjuvant in pharmacotherapy of PD. 
Additionally Betaine is safer drug with wide therapeutic 
window. 
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